Quick Answer
Anbio Biotechnology reported Cash and Equivalents of $11.76 million for fiscal year 2024.
Anbio Biotechnology Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $11.76M | +21.4% |
| 2023 | $9.69M | — |
- Anbio Biotechnology showed an increase of +21.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2024 period, Anbio Biotechnology’s cash and equivalents has grown by 21.4% (from $9.69 million to $11.76 million).
- The most recent figure is from Anbio Biotechnology’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 28, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: